醫藥和生技產業資產收購交易：2019-2026

本報告對全球生命科學產業的資產收購交易進行了全面分析。報告專為業務拓展、授權和企業策略專業人士設計，深入剖析了企業如何建立資產收購交易以及如何就相關財務條款進行談判。

這份經過全面修訂和更新的報告分析了自2019年以來公佈的資產收購協議，揭示了醫藥和生物技術公司如何透過策略交易獲取業務資產、產品資產、特許權使用費權益和技術資產。

每項交易記錄均包含可用的財務條款，並提供指向詳細線上交易記錄和已向監管機構提交的合約文件的連結。結合交易數據、財務基準和合約文件，用戶可以評估類似交易並制定更有效的資產收購策略。

主要優勢

• 顯著縮短研究時間

無需再搜尋多份新聞稿、資料庫和監管文件，即可存取統一的資產收購交易資料庫。

• 資產收購交易結構基準分析

您可以了解製藥和生技公司如何依業務部門、產品、技術和特許權使用費收入流建立資產收購協議。

• 財務條款分析

您可以查看公開的財務資訊（交易總額、預付款、里程碑付款、特許權使用費協議等），以對標交易價值和結構。

• 存取實際合約文件

您可以查看已向美國證券交易委員會 (SEC) 提交的資產收購協議（如有公開文件），以更深入地了解實際交易中的合約條款。

• 辨識最活躍的資產收購公司

我們辨識出資產收購領域最活躍的公司，並分析其策略交易活動。

• 追蹤產業趨勢

我們分析了自 2019 年以來，依公司、治療領域和技術類型劃分的資產收購交易趨勢。

目錄

摘要整理

第一章：引言

第二章：資產收購交易趨勢

• 收購資產類型
• 自 2019 年以來的資產收購交易趨勢
  • 依年份
  • 依研發階段
  • 依行業板塊
  • 依治療領域
  • 依技術分類
  • 最活躍的公司
• 進行資產收購交易的原因
  • 業務資產
  • 產品資產
  • 特許權使用費資產
  • 技術資產
• 資產收購交易的未來

第三章：資產收購交易架構概論

• 資產收購交易結構

第四章：主要資產收購交易

• 主要資產收購交易：以價值分類

第五章：最活躍的25家資產收購公司

• 最活躍的25家資產收購公司公司

第六章：合作協議目錄：包含協議

• 合作協議：包含協議
• 協定目錄
• 協議目錄 - 依公司（A-Z）分類
• 協議目錄 - 依治療領域分類
• 協定目錄 - 依技術分類
• 關於 Biopharma Research Ltd
• 當前合作關係
• 當前協議
• 近期合作報告標題

Benchmark Asset Acquisition Strategies Across the Global Biopharma Industry

Free report sample

The Asset Purchase Deals in Pharmaceuticals and Biotechnology 2019-2026 report provides a comprehensive analysis of asset acquisition transactions across the global life sciences industry. Designed for business development, licensing, and corporate strategy professionals, the report delivers detailed insight into how companies structure asset purchase deals and negotiate the financial terms behind these transactions.

Fully revised and updated, the report analyzes asset purchase agreements announced since 2019, providing a detailed view of how pharmaceutical and biotechnology companies acquire business assets, product assets, royalty interests, and technology assets through strategic transactions.

Each deal record includes financial terms where available and links to detailed online deal records and contract documents filed with regulators when publicly disclosed. This combination of deal data, financial benchmarking, and contract access enables users to evaluate comparable transactions and structure more effective asset acquisition strategies.

Key Benefits

• Save Significant Research Time

Access a consolidated database of asset purchase deals rather than searching multiple press releases, databases, and regulatory filings.

• Benchmark Asset Purchase Deal Structures

Understand how pharmaceutical and biotechnology companies structure asset acquisition agreements across business units, products, technologies, and royalty streams.

• Analyze Financial Terms with Confidence

Review disclosed financial information-including headline deal values, upfront payments, milestones, and royalty arrangements-to benchmark transaction values and structures.

• Access Real Contract Documents

Where available, explore SEC-filed asset purchase agreements, providing deeper insight into the contractual provisions behind real-world deals.

• Identify the Most Active Asset Acquisition Dealmakers

Discover which companies are most active in asset acquisitions and analyze their strategic transaction activity.

• Track Industry Trends

Analyze asset purchase dealmaking trends since 2019 across companies, therapeutic areas, and technology types.

What's Included in the Report

Analysis of asset purchase dealmaking trends since 2019

Overview of asset acquisition deal structures and transaction models

Review of the leading asset purchase deals by headline value

Profiles of the top 25 most active asset purchase dealmakers

Detailed analysis of deals organized by company, therapeutic area, technology type, and industry sector

A comprehensive deal directory covering asset purchase transactions announced since 2019

Links to online deal records and contract documents where available

Due Diligence Insights from Real Agreements

By reviewing actual asset purchase contracts, the report enables users to evaluate key transaction provisions such as:

• Asset ownership and transfer rights
• Financial payment structures and transaction values
• Intellectual property rights and technology transfer provisions
• Commercialization and development obligations
• Royalty structures and ongoing financial participation
• Contract duration and termination provisions
• Access to real agreements provides insight into the detailed terms negotiated between companies-information rarely disclosed in press releases or traditional deal databases.
• Why This Report Matters
• Asset purchase transactions are an important strategic tool in the pharmaceutical and biotechnology industries, enabling companies to acquire technologies, products, and royalty streams to strengthen their pipelines and portfolios.
• By combining comprehensive deal data, financial benchmarking, and access to real contract documents, this report provides the intelligence needed to evaluate acquisition opportunities, structure stronger asset purchase agreements, and negotiate more effectively.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in asset purchase dealmaking

• 2.1. Introduction
• 2.2. Types of assets purchased
• 2.3. Trends in asset purchase deals since 2019
  • 2.3.1. Asset purchase dealmaking by year
  • 2.3.2. Asset purchase dealmaking by phase of development
  • 2.3.3. Asset purchase dealmaking by industry sector
  • 2.3.4. Asset purchase dealmaking by therapy area
  • 2.3.5. Asset purchase dealmaking by technology type
  • 2.3.6. Asset purchase dealmaking by most active company
• 2.4. Reasons for entering into asset purchase partnering deals
  • 2.4.1. Business assets
  • 2.4.2. Product assets
  • 2.4.3. Royalty assets
  • 2.4.4. Technology assets
• 2.5. The future of asset purchase deals

Chapter 3 - Overview of asset purchase deal structure

• 3.1. Introduction
• 3.2. Asset purchase agreement structure

Chapter 4 - Leading asset purchase deals

• 4.1. Introduction
• 4.2. Top asset purchase deals by value

Chapter 5 - Top 25 most active asset purchase dealmakers

• 5.1. Introduction
• 5.2. Top 25 most active asset purchase dealmakers

Chapter 6 - Asset purchase deals including contracts directory

• 6.1. Introduction
• 6.2. Asset purchase deals with contracts
• Deal directory
• Deal directory - Asset purchase dealmaking by companies A-Z
• Deal directory - Asset purchase dealmaking by therapy area
• Deal directory - Asset purchase dealmaking by technology type
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

TABLE OF FIGURES

• Figure 1: Definition of assets purchased
• Figure 2: Trends in asset purchase deal announcements
• Figure 3: Asset purchase deals signed at each phase of development
• Figure 4: Asset purchase deals by industry sector
• Figure 5: Asset purchase deals by therapy area
• Figure 6: Asset purchase deals by technology type
• Figure 7: Top 25 most active asset purchase dealmakers
• Figure 8: Top asset purchase deals by value
• Figure 9: Most active asset purchase dealmakers